Ian T. Clark
Mr. Clark joined Genentech, Inc. in 2003 as senior vice president and general manager, BioOncology. He subsequently held a number of senior management positions and was appointed to CEO in January 2010 where he served until his recent retirement in December 2016. During his tenure, he led the Genentech Executive Committee and was a member of the Genentech Board of Directors. Prior to joining Genentech, Mr. Clark served as general manager of Novartis Canada and, before that, as chief operating officer for Novartis United Kingdom. Earlier in his career, Mr. Clark served as vice president of sales and marketing for Sanofi (Aventis) and for Ivax in the United Kingdom, France and Eastern Europe. Mr. Clark also serves on the boards of TerraVia Holdings, Inc., the Biotechnology Industry Organization (BIO) and the Gladstone Foundation, an independent, nonprofit life science research organization. He also serves as an advisor to the Institute of Life Sciences at Southampton University in the United Kingdom, as a member of the Federal Reserve Bank of San Francisco s Economic Advisory Council, and as a member of the Technology Network Executive Council. Mr. Clark received a Bachelor of Science and an honorary doctorate in biological sciences from Southampton University.
Elisha P. ( Terry ) Gould
Mr. Gould is a Partner and Head of Venture/Growth Equity Investments with Adam Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. Mr. Gould also sits on the board of directors of OncoMed Pharmaceuticals, Inc. (NADSAQ:OMED), LifeBond, Ltd. and Orbus Therapeutics, Inc. He was a former board member at Naurex, Inc. (acquired by Allergan plc), INC Research, Inc., Incline Therapeutics, Inc. (acquired by the Medicines Company) and Proteus Biomedical, Inc. Mr. Gould is also a member of the Adams Street Executive and Direct Investment Committees.
Steve E. Krognes
Mr. Krognes is currently Chief Financial Officer of Denali Therapeutics Inc., a biotechnology company. He has served as Senior Vice President and Chief Financial Officer at Genentech, Inc., a biotechnology company, and as Head of Mergers Acquisitions at Roche Holding AG, a biotechnology company. Mr. Krognes is also a member of the board of directors of the California Academy of Sciences, a scientific and educational institution, and was previously a member of the board of directors and board executive committee of the California Life Sciences Association, an industry organization. Mr. Krognes received a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Richard A Miller, M.D.
Dr. Miller is Corvus President and Chief Executive Officer. He was previously co-founder and CEO of Pharmacyclics where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Bioden IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D., summa cum laude, from the State University of New York Medical School and is currently Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center.
Peter Moldt, Ph.D.
Dr. Moldt has been a partner at Novo Ventures (US) since May 2012. He is chairman of the board of directors of Allakos Inc., and a member of the board of directors of Cardeas Pharma. From 2009 to May 2012, Dr. Moldt was employed with Novo A/S as a partner. In 2004, he co-founded Curalogic A/S, a Danish pharmaceutical company, where he served as CEO until 2009 and took the company public on the Copenhagen Stock Exchange in 2006. From 2000 to 2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a Ph.D. in Pharmacy and Medicinal Chemistry from the Royal Danish School of Pharmacy and holds a post doctorate in the Department of Organic Chemistry at Yale University.
Scott W. Morrison
Mr. Morrison was a Partner with Ernst Young LLP from 1996 to December 2015, where he also served as U.S. Life Sciences Leader from 2002 through December 2015. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Since January 2016, Mr. Morrison serves on the board and chairs the audit committees of Global Blood Therapeutics and Audentes Therapeutics. Since 1999, he has served on the board of directors of the Biotechnology Institute, a nonprofit organization, where has also served on the audit committee since 2002. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, a biotechnology nonprofit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Industry Organization, a trade organization.
Peter Thompson, M.D.
Dr. Thompson is currently a Private Equity Partner with OrbiMed Advisorswho brings over 20 years of industry experience. He co-founded and was CEO of Trubion Pharmaceuticals, co-founded Cleave BioSciences and serves as a director on the boards of several public and private companies. He previously held executive positions at Chiron Corporation and Becton Dickinson. Dr. Thompson is an Ernst Young Entrepreneur of the Year awardee, an Affiliate Professor of Neurosurgery at the University of Washington, an inventor on numerous patents, and a board-certified internist and oncologist.